Ingevity stock has delivered a 29.6% gain over the past three years, yet the current valuation checks point to a mixed picture rather than a clear bargain or clear overvaluation. Recent share price weakness adds another layer of complexity, with the stock pulling back over the past month even as multi year returns remain positive.
- Ingevity has returned 29.6% over three years, which raises the question of how much of the business improvement story is already reflected in the share price.
- Future cash generation from specialty chemicals and materials can support the current valuation, while any pressure on margins or slower contract wins may weigh on what investors are willing to pay.
- The broader checks show a mixed picture, with the stock priced in line with neither a clear bargain nor an obvious premium when viewed across valuation factors, as reflected in its value score of 3.
The issue now is whether Ingevity’s recent pullback has created enough pricing support for new buyers or if the current level already assumes too much good news.
Compare Ingevity’s mixed valuation story with other businesses that pair balance sheet strength and fundamentals by scanning the solid balance sheet and fundamentals stocks screener (23 results) for potential alternatives in similar situations.
Is Ingevity Getting Expensive on Earnings?
The P/E ratio is a straightforward way to see what investors are paying today for each dollar of Ingevity earnings. On this yardstick, the picture is punchy. Ingevity trades on a P/E of 91.6x, far above the broader chemicals industry average of 24.2x and also ahead of the 26.1x peer group level. That is a steep premium for a mid sized materials business, and it indicates that the market is attaching a high price tag to the current profit base.
The fair P/E that emerges from the broader checks is 33.6x. That figure already reflects the company specific profile, including its sector, risk and earnings quality. Compared with the current 91.6x, Ingevity is priced at close to three times that implied level, which leaves little room for disappointment in upcoming results.
On earnings multiples alone, Ingevity stock currently screens as overvalued.
See what the numbers say about this price — find out in our valuation breakdown.
The Ingevity Narrative: What Would Justify Today's Price?
Ingevity Narratives on Simply Wall St pick up where the valuation puzzle leaves off and spell out exactly which expectations on growth, margins and earnings would need to hold for the shares to be worth materially more or less than today’s price. Each scenario ties a fair value estimate to a clear storyline about Ingevity’s potential catalysts and pressure points so you can track over time which version of events is actually unfolding in the real world.
Share a Narrative on Ingevity, present a data-driven case on its growth, margins, and execution going forward, and then compare your thesis with the company’s results as they are released.
Do you think there's more to the story for Ingevity? Head over to our Community to see what others are saying!
The Bottom Line
On current multiples, Ingevity looks overvalued, with the rich P/E doing most of the heavy lifting in the market view. The broader checks point to a mixed rather than outright cheap profile, so the case now leans heavily on whether earnings delivery can eventually grow into that premium. The real swing factor from here is simple. Either margins and execution improve enough to make today’s price look reasonable, or the P/E multiple does the work instead by drifting closer to industry levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com